PPAR-α targeting in kidney fibrosis: is BAY PP1 just another renoprotector?

Abstract

Interstitial fibrosis plays a major role in the progression of renal diseases. Peroxisome proliferator-activated receptor-α (PPAR-α) ligands are increasingly explored for their potential to reverse or halt tubulointerstitial fibrosis. This Commentary discusses new findings by Boor et al., who show that BAY PP1, a novel PPAR-α agonist, ameliorates renal fibrosis and dysfunction.

• Authors: Wafa M Elbjeirami
• Journal: Kidney international (Kidney Int) Vol. 80 Issue 11 Pg. 1115-7 (Dec 2011) ISSN: 1523-1755 [Electronic] United States
• PMID: 22083634 (Publication Type: Journal Article, Comment)

Chemical References

• 2-((4-(((2-methoxyethyl)(6-(3-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)methyl)phenyl)sulfanyl)-2-methylpropanoic acid
• Peroxisome Proliferator-Activated Receptors
• Pyrimidines
• 3-Mercaptopropionic Acid

Topics

• 3-Mercaptopropionic Acid (analogs & derivatives, therapeutic use)
• Animals
• Fibrosis (prevention & control)
• Kidney Diseases (drug therapy)
• Peroxisome Proliferator-Activated Receptors (agonists)
• Pyrimidines (therapeutic use)